$19.25+1.29% 1DFinazon · prior-day close · Sep 4, 2026
Price · Chart
Our own end-of-day closes61 sessions
$22.5$12.510 Jun4 Sep
The line runs $13 on 10 June through $19.25 on 4 September, on a scale from $12.5 to $22.5. Days the market did not trade hold the previous close, flat.
The chart above plots the price of AVTX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 61 sessions over that window: $13 on 10 June 2026 through $19.25 on 4 September 2026.
Market cap$1.0B
52-week range$9 – $24
Avg volume114.1K
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 8, 2026
AVTX insider trades
SEC Form 4 · last 90 days · newest reported trade 28 Aug 2026
Open-market buys0
Open-market sells9
Net sold$1.69M
Non-trade filings12
DateInsiderTypeSharesValue
28 Aug 2026Doyle MittieChief Medical OfficerSell679$14K
18 Aug 2026Sullivan Christopher RyanChief Financial OfficerSell31,031$622K
17 Aug 2026Sullivan Christopher RyanChief Financial OfficerSell41,694$828K
17 Aug 2026Doyle MittieChief Medical OfficerSell1,000$20K
11 Aug 2026Riley JenniferChief Strategy OfficerSell2,655$52K
10 Aug 2026Doyle MittieChief Medical OfficerSell679$14K
27 Jul 2026Doyle MittieChief Medical OfficerSell1,000$20K
30 Jun 2026Doyle MittieChief Medical OfficerSell4,654$93K
23 Jun 2026Doyle MittieChief Medical OfficerSell1,450$26K
Compensation mechanics
Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
DateInsiderTypeSharesValue
28 Aug 2026Doyle MittieChief Medical OfficerOption exercise679$5K
18 Aug 2026Sullivan Christopher RyanChief Financial OfficerOption exercise31,031$307K
17 Aug 2026Sullivan Christopher RyanChief Financial OfficerOption exercise40,821$403K
17 Aug 2026Doyle MittieChief Medical OfficerOption exercise1,000$13K
10 Aug 2026Doyle MittieChief Medical OfficerOption exercise679$5K
27 Jul 2026Doyle MittieChief Medical OfficerOption exercise1,000$13K
30 Jun 2026Doyle MittieChief Medical OfficerOption exercise4,654$51K
23 Jun 2026Doyle MittieChief Medical OfficerOption exercise1,450$12K
10 Jun 2026VARKI PAULChief Legal OfficerTax withheld1,081$14K
10 Jun 2026Sullivan Christopher RyanChief Financial OfficerTax withheld138$2K
10 Jun 2026Doyle MittieChief Medical OfficerTax withheld1,084$14K
10 Jun 2026Riley JenniferChief Strategy OfficerTax withheld588$8K
AVTX reported financials
SEC EDGAR XBRL
AVTX reported revenue of $59K for the fiscal year ended 31 Dec 2025. Net income over the same period was −$78.3M.
FigureReportedPeriod
Revenue
$59K
31 Dec 2025 fiscal year
Net income
−$78.3M
31 Dec 2025 fiscal year
Diluted EPS
−$5.84
31 Dec 2025 fiscal year
Total assets
$490.8M
30 Jun 2026 at period end
Total equity
$448.7M
30 Jun 2026 at period end
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
AVTX earnings
SEC EDGAR
DatePeriodEPSRevenue
30 Jun 2026Q2 2026$-0.83—
31 Mar 2026Q1 2026$-0.98—
31 Dec 2025FY 2025$-5.84—
30 Sep 2025Q3 2025$-2.19—
30 Jun 2025Q2 2025$-1.92—
31 Mar 2025Q1 2025$-1.25—
31 Dec 2024FY 2024$-20.91—
30 Sep 2024Q3 2024$-2.83—
Next report no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
7 of the 45 institutional funds we track reported a AVTX position for the quarter ended 30 Jun 2026 — a combined $84.7M; the latest of those filings landed 02 Sep 2026.